tiprankstipranks

IceCure’s ProSense® Cryoablation Showcased at St. Gallen Breast Cancer Conference

Story Highlights
  • IceCure Medical’s ProSense® Cryoablation was featured in six studies at the St. Gallen Breast Cancer Conference.
  • The studies highlight ProSense® as an effective alternative to surgery for early-stage breast cancer, enhancing IceCure’s industry position.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
IceCure’s ProSense® Cryoablation Showcased at St. Gallen Breast Cancer Conference

Icecure Medical ( (ICCM) ) has issued an update.

IceCure Medical announced that its ProSense® Cryoablation technology was featured in six studies presented at the St. Gallen International Breast Cancer Conference held in Vienna, Austria, from March 12-15, 2025. The studies, which will be published in the journal ‘The Breast,’ highlight the system’s potential as a viable alternative to surgical tumor removal, particularly in early-stage breast cancer, and demonstrate its growing acceptance in the medical community. The studies suggest that ProSense® can effectively treat various breast cancer subtypes, including those in younger patients and those with triple-negative breast cancer, with a high rate of complete tumor ablation and minimal adverse effects, positioning IceCure as a leader in innovative cancer treatments.

More about Icecure Medical

IceCure Medical, listed on Nasdaq as ICCM, develops and markets advanced cryoablation therapy systems using liquid nitrogen for tumor destruction, focusing on breast, kidney, bone, and lung cancers. Their minimally invasive technology offers a safe and effective alternative to traditional surgical tumor removal, with their flagship ProSense® system marketed globally in regions including the U.S., Europe, and China.

YTD Price Performance: 23.58%

Average Trading Volume: 353,321

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $80.33M

For a thorough assessment of ICCM stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App